血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂对非酒精性脂肪性肝病的疗效及作用机制（英文）  

Therapeutic effect and mechanism of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on non-alcoholic fatty liver disease

作　　者：李锦忠 谌宁 王丹[1] 龚晓兵[1] LI Jinzhong;CHEN Ning;WANG Dang;GONG Xiaobing(Department of Gastroenterology,the First Affiliated Hospital of Jinan University,Guangzhou 510632,China)

机构地区：[1]广州市暨南大学第一附属医院消化科,广东广州510632

出　　处：《暨南大学学报（自然科学与医学版）》2018年第4期306-316,共11页Journal of Jinan University(Natural Science & Medicine Edition)

基　　金：国家自然科学基金项目(81671946);广东省医学科学技术研究基金项目(A2015479)

摘　　要：目的:研究血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂(ACEIs/ARBs)对于非酒精性脂肪性肝病的疗效及作用机制.方法:从新旧RAS系统、胰岛素抵抗、氧化应激、脂肪细胞因子等方面研究了非酒精性脂肪性肝病的发病机制及ACEIs/ARBs的治疗效果和作用机制.结果:ACELs/ARBs可通过调节脂肪细胞因子、抑制炎症因子的释放和肝星状细胞的激活等途径改善患者的胰岛素抵抗、脂质沉积、肝脏炎症及纤维化.结论:通过对NAFLD的发病机制及ACEI或ARB可能的作用途径的研究,给NAFLD的治疗提供了一个新的方向和理论依据.Objective： To study the efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers（ ACEIs/ARBs） in the treatment of non-alcoholic fatty liver disease（ NAFLD）. Methods： The review studied the mechanisms of NAFLD and the therapeutic effect and mechanisms of ACEIs/ARBs from aspects of new and old RAS system,insulin resistance,oxidative stress,and adipocytokines,respectively. Results： ACEIs/ARBs improve the insulin resistance,lipid deposition,liver inflammatory and fibrosis of patients by regulating adipokines,inhibiting the release of inflammatory cytokines and activation of hepatic stellate cells. Conclusion： The review provides a new direction and theoretical evidence for the treatment of NAFLD by studying the pathogenesis of NAFLD and the possible action pathways of ACEIs/ARBs.

关 键 词：非酒精性脂肪性肝病 血管紧张素转换酶抑制剂 血管紧张素受体拮抗剂 作用机制 

分 类 号：R575.1[医药卫生—消化系统] R453.9[医药卫生—内科学]